DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS Paolo Manfredi, chief scientific officer at Relmada Therapeutics, remarked, “This designation further supports the potential of REL-1017 as a paradigm-shifting, novel standalone treatment for MDD, and highlights the significant unmet medical need in a therapeutic area where little has changed over the last several decades: available treatments remain inadequate for the majority of patients with MDD.”
Peer-influenced content. Sources you trust. No registration required. This is HCN.